Benchmarking evolutionary tinkering underlying human-viral molecular mimicry shows multiple host pulmonary-arterial peptides mimicked by SARS-CoV-2.
Environmental microbiology
Proteomics
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
08
2020
accepted:
01
09
2020
entrez:
7
10
2020
pubmed:
8
10
2020
medline:
8
10
2020
Statut:
epublish
Résumé
The hand of molecular mimicry in shaping SARS-CoV-2 evolution and immune evasion remains to be deciphered. Here, we report 33 distinct 8-mer/9-mer peptides that are identical between SARS-CoV-2 and the human reference proteome. We benchmark this observation against other viral-human 8-mer/9-mer peptide identity, which suggests generally similar extents of molecular mimicry for SARS-CoV-2 and many other human viruses. Interestingly, 20 novel human peptides mimicked by SARS-CoV-2 have not been observed in any previous coronavirus strains (HCoV, SARS-CoV, and MERS). Furthermore, four of the human 8-mer/9-mer peptides mimicked by SARS-CoV-2 map onto HLA-B*40:01, HLA-B*40:02, and HLA-B*35:01 binding peptides from human PAM, ANXA7, PGD, and ALOX5AP proteins. This mimicry of multiple human proteins by SARS-CoV-2 is made salient by single-cell RNA-seq (scRNA-seq) analysis that shows the targeted genes significantly expressed in human lungs and arteries; tissues implicated in COVID-19 pathogenesis. Finally, HLA-A*03 restricted 8-mer peptides are found to be shared broadly by human and coronaviridae helicases in functional hotspots, with potential implications for nucleic acid unwinding upon initial infection. This study presents the first scan of human peptide mimicry by SARS-CoV-2, and via its benchmarking against human-viral mimicry more broadly, presents a computational framework for follow-up studies to assay how evolutionary tinkering may relate to zoonosis and herd immunity.
Identifiants
pubmed: 33024578
doi: 10.1038/s41420-020-00321-y
pii: 321
pmc: PMC7529588
doi:
Types de publication
Journal Article
Langues
eng
Pagination
96Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
J Clin Invest. 2016 Dec 1;126(12):4690-4701
pubmed: 27841757
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Viruses. 2019 Aug 19;11(8):
pubmed: 31430946
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515
pubmed: 30395287
Immunity. 2017 Feb 21;46(2):315-326
pubmed: 28228285
Curr Biol. 2020 Apr 6;30(7):1346-1351.e2
pubmed: 32197085
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Mol Cell Proteomics. 2019 Nov;18(11):2298-2309
pubmed: 31530632
Lancet. 2020 Jun 6;395(10239):1741-1743
pubmed: 32410759
Curr Protoc Immunol. 2013 Feb;Chapter 18:Unit 18.3.
pubmed: 23392640
Circulation. 2020 May 17;:
pubmed: 32418446
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Clin Microbiol Rev. 2006 Jan;19(1):80-94
pubmed: 16418524
Elife. 2020 Jul 07;9:
pubmed: 32633720
Immunol Rev. 2013 Sep;255(1):197-209
pubmed: 23947356
Proteomics. 2018 Jun;18(12):e1700253
pubmed: 29437277
Sci Adv. 2020 Jul 1;6(27):
pubmed: 32937441
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
Autoimmun Rev. 2020 May;19(5):102524
pubmed: 32220633
Elife. 2020 May 28;9:
pubmed: 32463365
J Immunol. 2016 Feb 15;196(4):1480-7
pubmed: 26783342
Front Immunol. 2017 Mar 14;8:278
pubmed: 28352270
Nucleic Acids Res. 2015 Jan;43(Database issue):D405-12
pubmed: 25300482
Nucleic Acids Res. 2009 Jan;37(Database issue):D436-42
pubmed: 18981051
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Otolaryngol Head Neck Surg. 2020 Sep;163(3):473-479
pubmed: 32513096
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391